Background-␤-Blockers and ACE inhibitors reduce early mortality when either one is started in the first hours after myocardial infarction (MI). Considering the close correlation between morphological changes and prognosis, we aimed to investigate whether the benefit of both ␤-blockers and ACE inhibitors might reside in a similar protective effect on infarct size or ventricular volume. Methods and Results-In a randomized, double-blind comparison between early treatment with captopril or atenolol in 121 patients with acute anterior MI, both drugs showed a similar reduction in mean blood pressure. However, only the atenolol-treated patients showed a significant early reduction in heart rate. Infarct size, obtained from the perfusion defect in resting single photon emission imaging, was higher in captopril-treated patients than in atenolol-treated patients: 29.8Ϯ12% versus 20.8Ϯ12% (PϽ0.01) by polar map and 28.3Ϯ13% versus 20.0Ϯ13% (PϽ0.01) by tomography. Changes from baseline to 1 week and to 3 months in ventricular end-diastolic volume, assessed by echocardiography, were as follows: 58Ϯ14 versus 64Ϯ19 (PϽ0.05) and 65Ϯ21 mL/m 2 (PϽ0.05), respectively, with captopril, and 58Ϯ18 versus 64Ϯ18 (PϽ0.05) and 69Ϯ30 mL/m 2 (PϽ0.05), respectively, with atenolol. Neither group showed significant changes in end-systolic volume. Among patients with perfusion defect Ͼ18% (nϭ51), those treated with atenolol showed a significant increase of end-systolic and end-diastolic ventricular volumes, whereas captopriltreated patients did not. Conclusions-Although early treatment with atenolol or captopril results in similar overall short-and medium-term preservation of ventricular function and volumes, in patients with larger infarctions, a ␤-blocker alone does not adequately protect myocardium from ventricular dilatation. (Circulation. 2001;103:813-819.)
B oth ␤-blockers and ACE inhibitors improve long-term survival rates in patients when administered after the acute phase of myocardial infarction (MI), 1,2 a benefit mainly observed in high-risk patients. [3] [4] [5] These are not the only links between ␤-blockers and ACE inhibitors, because both pharmacological agents seem to be able to attenuate underlying neurohormonal activation in ventricular dysfunction, 6 both reduce the incidence of sudden death, 1, 5, 7 and the antiischemic effect appears not to be a property exclusive to ␤-blockers. 8, 9 A further finding common to both ACE inhibitors and ␤-blockers is the reduction in early mortality when treatment is initiated in the first hours of MI. 3, 10 Given that the prognosis of MI depends in great measure on the early morphological impact, 11 it may be that the benefits common to both drugs are the consequence of a similar preservation effect on ventricular geometry. The protective effect of ACE inhibitors on cardiac anatomy has been documented repeatedly in clinical studies, [12] [13] [14] [15] [16] whereas we have experimental evidence that ␤-blockers increase ventricular dilatation, 17, 18 and only the reduction of the risk of cardiac rupture attributed to ␤-blockers 19 suggests a favorable effect on protecting the ventricular wall. On the other hand, early use of ␤-blockers seems to limit infarct size, whereas for ACE inhibitors, this effect has been reported only in experimental models. 20 With all this in mind, the present study was designed to compare the effect of early treatment with atenolol or captopril on ventricular dilatation and to determine whether our findings might be explained by each drug's having a different effect on limiting infarct size.
Methods Patients
We conducted a prospective study on consecutive patients admitted to the Coronary Care Unit of the Hospital Virgen de la Arrixaca, Murcia, Spain, for suspected large anterior MI Ͻ24 hours from the onset of symptoms, established by the presence of a typical precordial pain lasting Ն30 minutes and an increase of Ͼ0.1 mV in ST displacement in Ͼ3 leads from V 1 to V 6 . Diagnosis of Q-wave MI was confirmed by both new Q-wave appearance and an increase in creatine kinase (CK) to more than twice the normal value (190 U/L). Exclusion criteria were any of the following: informed consent not given, left bundle-branch block, age Ͼ75 years, Killip class ϾII, myocardiopathy or valvular disease, atrial fibrillation, bradycardia Ͻ50 bpm, any degree of AV block, a history of asthma or bronchitis requiring bronchodilators, systolic blood pressure Ͻ95 mm Hg, renal impairment (serum creatinine Ͼ0.2. mmol/L), or any other serious concomitant disease. Thrombolytic therapy was based on clinical criteria, and indirect reperfusion criteria were considered, according to standard protocols, 21 in the presence of 2 or more of the following: (1) CK peak Ͻ14 hours from the onset of pain; (2) 50% decrease in the ST segment 2 hours after the start of thrombolysis compared with the baseline value; or (3) early relief of pain associated with reperfusion arrhythmias (thrombolysis-related accelerated idioventricular rhythm or sinus bradycardia). The study protocol was approved by the Hospital Human Research Committee and by the Dirección General de Farmacia del Instituto Nacional de la Salud.
Medication Protocol
Randomized, double-blind treatment with captopril or atenolol was started as soon as possible after informed consent was obtained. Initially, all patients received a first intravenous dose of 5 mg of atenolol or placebo administered over 5 minutes, and if this was well tolerated (no fall of systolic blood pressure below 95 mm Hg or bradycardia below 45 bpm), another equal dose was given 10 minutes later. Simultaneously with the first intravenous dose of atenolol or placebo, an oral dose of placebo or 6.25 mg of captopril, respectively, was given. Subsequent doses were as follows: second dose, captopril 12.5 mg or atenolol 33 mg 30 minutes after the first dose; third dose, captopril 25 mg or atenolol 33 mg 4 hours after the second dose; and thereafter, captopril 25 mg or atenolol 33 mg every 8 hours. To "blind" this procedure, the Hospital Pharmacy Service prepared ampoules of atenolol or placebo, first-dose capsules containing 6.25 mg of captopril or placebo, second-dose capsules containing 12.5 mg of captopril or 33 mg of atenolol, and capsules for successive doses containing 25 mg of captopril or 33 mg of atenolol. Target dose was 25 mg of captopril or 33 mg of atenolol every 8 hours. If hypotension and/or bradycardia occurred, medication was stopped, and after recovery, the next dose was given. Study medication was discontinued if MI was not confirmed or if the patient developed any of the following complications: sustained hypotension (systolic blood pressure Ͻ90 mm Hg for Ͼ3 hours) or symptomatic hypotension; heart failure, Killip class ϾII; recurrence of ischemic pain; or recurrent MI. For the purposes of this study, post-hospital-discharge medication was supplied to each patient by the Pharmacy Service during follow-up according to group.
Radionuclide Determinations
Resting single photon emission tomography with 99m Tc hexakis 2-methoxyisobutyl isonitrile imaging (MIBI-SPECT) was performed on the fifth day with a rotating gamma camera (Apex SP4, Elscint) equipped with a high-resolution collimator. Sixty frames (64ϫ64 matrix) were acquired for 25 seconds each over 180°in 3 intervals, starting in the right anterior oblique position and ending in the posterior oblique position. The energy window was centered on the 140-keV gamma photopeak. Quantification of the size of the perfusion defect (myocardial infarct size), expressed as a percentage of the total left ventricle, was calculated by tomographic 22 and polar map 23 methods. Intraobserver variability for both methods of quantification was 9% and 4%, respectively. Perfusion study imaging was performed only in those patients who did not develop reinfarction and who fulfilled the following criteria: confirmation of infarction, no antecedents of a prior infarction, and no early violation of the study medication protocol.
Echocardiography
2D echocardiography was performed with Sonos 1000 (Hewlett-Packard) and a 2.5-MHz transducer. We used apical 4-and 2-chamber views to determine left ventricular ejection fraction and left ventricular volumes using the biplane summation-of-disks method recommended by the American Society of Echocardiography. 24 Left ventricular ejection fraction and left ventricular volumes were assessed within the first 24 hours after admission, at 1 week, and at 3 months. The reproducibility of ventricular volume measurements made by the same observer differed by 8.5% for left end-diastolic volume and by 6.7% for left end-systolic volume. Left ventricular end-diastolic volume index and left ventricular endsystolic volume index were derived by means of body surface area.
Coronary Angiography
To compare the extent of coronary disease and infarct-related coronary artery patency between captopril and atenolol groups, left catheterization with multiple views of the coronary tree was performed in all surviving patients on day 10. Coronary angiograms were analyzed by an observer unaware of the patients' clinical status. Significant coronary stenosis was defined as a narrowing of Ն60% of the lumen. Vessel patency was established according to TIMI grades. 25 
Statistical Analysis
A descriptive analysis was done on all variables to obtain a frequency distribution. For the quantitative variables, we also determined the mean, median, SD, and range. The relationship between categorical variables was assessed by means of contingency tables, the 2 test, and an analysis of residues to test the trend of associations or dependence. Between-group comparisons were studied by ANOVA complemented with means equality contrasts using the Student's t test. Changes from baseline to subsequent measurements in ventricular volume and ejection fraction were compared by paired t test in the overall population with radionuclide perfusion defect and in the subgroup of patients with "larger" infarctions, empirically defined as the upper and middle tertiles of the perfusion defect. The level of significance was PϽ0.05. Variables with hypothetical influence on ventricular dilatation, such as age, sex, history of diabetes, hypertension, heart rate and blood pressure at admission, treatment group, baseline and 1-week left ventricular ejection fractions, perfusion defect, and TIMI grade of infarct-related artery, were introduced into a logistic regression analysis to determine their independent predictive value for a 15% increase of end-systolic volume index from baseline to 1 week and from baseline to 3 months. The statistical package used was SPSS.
Results
During the period of study, 121 patients were randomized to receive the study medication; 59 were allocated to receive captopril and 62 atenolol. Medication with captopril or atenolol was started at an average of 320 and 310 minutes, respectively, from the onset of symptoms. The captopriltreated patients were older, almost to statistical significance, and contained a smaller proportion of women. The remaining clinical characteristics and details at admission were similar in the 2 groups (Table 1) . Both captopril-and atenolol-treated patients showed a similar and significant reduction in mean blood pressure after 15 minutes of their respective first dose. However, only the atenolol-treated patients showed a significant early reduction in heart rate (Figure 1 ). In 10 patients in the atenolol group and 3 in the captopril group, a systolic blood pressure Ͻ90 mm Hg was recorded on at least 1 occasion. Reasons for withdrawal from medication are listed in Table 2 and include complications that appeared early, within the first 48 hours, and during the rest of the hospital stay.
Four patients, 2 in each group of treatment, were excluded from echocardiographic volume measurements because of inadequate image quality. Clinical characteristics and details of admission of patients with radionuclide perfusion defect in whom changes in ventricular volume were evaluated are expressed in Table 3 .
Among the patients in whom resting MIBI-SPECT was performed (45 patients treated with captopril and 49 treated with atenolol), perfusion defect was higher in those who received captopril: 29.8Ϯ12% versus 20.8Ϯ12% (PϾ0.01) by polar map and 28.3Ϯ13% versus 20.0Ϯ13% (PϽ0.01) by tomography. For other indirect indices of infarct size in these patients, differences reached statistical significance only in the case of peak CK. There were no significant differences between groups in subacute catheterization (Table 4) .
Subsequent revascularization was performed in 14 patients in the captopril group, 1 surgically and 13 by angioplasty, and 
Total, n (early) 12 (4) 11 (8) Early indicates within the first 48 hours after randomization.
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in 12 patients in the atenolol group, 2 surgically and 10 by angioplasty. After hospital discharge, 1 patient in the captopril group was openly treated with ␤-blockers for sinusal tachycardia.
In both groups, left ventricular ejection fraction was similar and showed no significant changes from baseline to 1 week. In both groups, the end-diastolic volume index increased slightly but significantly. In the medium term, both treatment groups showed significant improvement of left ventricular ejection fraction with a similar end-systolic volume, without significant changes in the end-diastolic volume evaluated at 1 week ( Table 5 ). The patients with perfusion defect imaging in the middle and upper tertiles (Ն18%; 28 in the captopril group and 23 in the atenolol group) experienced a different medium-term evolution in that those treated with atenolol underwent a significant increase of ventricular volume (Figure 2) .
In the logistic regression analysis, left ventricular ejection fraction at 1 week was the only variable with independent predictive value for an increase of end-systolic ventricular volume from baseline to 1 week (OR 2.9, 95% CI 1.34 to 6.2), whereas perfusion defect was the only variable with independent predictive value for an increase of end-systolic volume from baseline to 3 months (OR 7.9, 95% CI 2.3 to 27.2).
Discussion
Considering the close correlation between morphological changes and prognosis, 11 it seems obligatory to investigate whether the benefit of both ␤-blockers and ACE inhibitors in early mortality might result from a common protective effect on ventricular architecture, but although comparative studies have been called for, 14 little has been done to determine to what extent the similar benefit of ␤-blockers arises from an equal or from a different effect on ventricular dilatation. Moreover, if there are no contraindications, simultaneous early treatment with ␤-blockers and ACE inhibitors is recommended in the case of anterior acute MI, 26 although the clinician frequently questions which of the 2 drugs should have priority, especially when blood pressure is not elevated.
In the present study, early administration of either captopril or atenolol was followed by a significant early decrease in blood pressure. Considering the importance of afterload in the early expansion of the infarcted wall segment, 27 it would be reasonable to expect from both drugs a similar benefit on ventricular dilatation in the short-term. However, cardiac output either does not change 15 or increases slightly 28 when captopril is administered early in patients with infarction, whereas cardiac output usually diminishes with the early administration of ␤-blockers. 29 Therefore, captopril would seem to reduce to a greater degree the vascular systemic resistances and consequently the risk of ventricular expansion. 30 However, the elongation of the infarcted segment depends not only on hemodynamic determinants but also on infarct size. In this respect, a rapid fall in heart rate accom- panied the fall in blood pressure only in the case of atenolol, a combined effect that, in theory, seems ideal to reduce myocardial oxygen demand and infarct size. 29 In accordance with this presumption, our results showed that patients who received atenolol showed a lesser MIBI-SPECT perfusion defect, with no differences between groups with respect to admission delay, initial ECG, rates of thrombolytic therapy, indirect reperfusion criteria, initial left ventricular ejection fraction, or subacute coronary anatomy. Therefore, although immediate angiographic reperfusion was not evaluated, it seems unlikely that the differences found in perfusion defect would lie in causes found outside the medication under study. Nevertheless, the fact remains that the difference in the estimation of infarct size with MIBI-SPECT was surprisingly marked. In this regard, is possible that the difference observed in the perfusion defect between the 2 treatment groups does not express the differences in true infarct size and that atenolol may have brought about a more rapid recuperation of cellular ischemia and more rapid uptake of 99m Tc isonitrile. 23 In any case, other indirect indices of infarct size, although they did not always reach statistical significance, always favored treatment with atenolol and strongly suggested its protective effect on myocardium. Curiously, even in the presence of this difference in perfusion defect, both treatments resulted in a similar ventricular end-systolic volume in the short term. The similar influence on ventricular volumes shown by both pharmacological agents in the present study is, in the case of atenolol, a finding contrary to that documented in a model of MI in the rat in which treatment with ␤-blockers caused a striking increase in left ventricular cavity dimensions. 17, 18 This difference in findings may be explained by the relatively late start of medication in those models, the second day 17 or fifth day 18 after coronary ligation, whereby the possible early hemodynamic benefits on infarct size and expansion would be lost. Moreover, the ventricular dilatation observed in these animal studies was in part attributed to the blunting of the hypertrophy of the noninfarcted myocardium, and as suggested by our results, it is probable that the increase in ventricular volume, conditioned by the treatment with ␤-blockers, is produced only in relatively large infarctions and might require the 4 or 5 weeks in which ventricular dilatation was documented in those studies. 17, 18 Although the protective effect of ␤-blockers on the ventricular morphology in the medium and long term may vary depending on the experimental model 31 or on the vasodilatory action of some ␤-blockers, 32 our results suggest that treatment with a ␤-blocker alone does not adequately protect patients with large infarctions from ventricular dilatation in the medium term.
Finally, our regression analysis points to depressed systolic function and infarct size as the predictive factors for ventricular dilatation and suggests in which way ACE inhibitors and ␤-blockers may overlap and result in an additive benefit, 33, 34 thus supporting the recommendation of the combined use of both drugs in acute anterior infarction. 26 According to the present results, in the absence of contraindications in patients with anterior MI in the first hours of evolution, toleration of ␤-blockers should be established as a priority. Given that the benefit of an ACE inhibitor can be observed in the first few days of evolution, 3 its association with ␤-blockers should not be delayed unnecessarily. In patients with large infarctions in whom the instigation of treatment with both drugs results in hypotension, withdrawal from ␤-blockers must be considered first.
